ADPT
Adaptive Biotechnologies Corp
29.60$
+6.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.9% | -6.2% | -5.7% | -4.5% | -3.4% | -5.3% | -2.8% | -1.2% | +4.5% | -1.3% | +26.6% | |
| – | -5.8% | -8.8% | -6.0% | -12.3% | -8.0% | -9.6% | +2.1% | +7.5% | +6.7% | -2.8% | +44.1% | |
| – | -26.7% | +9.5% | -16.0% | -36.3% | +25.8% | +5.7% | -14.8% | +27.5% | +28.1% | +10.1% | +119.0% | |
| – | -6.7% | -10.8% | -5.5% | -16.6% | -8.6% | -13.0% | +2.3% | +7.5% | +6.7% | -3.8% | +57.7% | |
| – | +21.7% | +10.7% | -15.3% | +14.6% | +2.2% | +4.4% | +1.6% | +4.6% | +8.7% | -4.1% | +2.5% | |
| – | -25.9% | -8.0% | -0.6% | -9.5% | -29.4% | +2.9% | -3.2% | +18.2% | -1.1% | +14.1% | -6.3% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -7.7% | -8.2% | -9.0% | -10.0% | -11.1% | -12.2% | -14.1% | -16.6% | -19.9% | -24.3% | -32.4% | |
| – | -0.9% | -2.1% | -0.6% | -2.5% | +0.6% | -4.8% | -1.1% | -9.7% | +0.5% | -2.1% | +73.9% | |
| – | -5.7% | -5.8% | +6.2% | -0.6% | +11.9% | -10.4% | +4.9% | -9.5% | +7.9% | -3.2% | +0.8% | |
| – | -1.0% | +2.2% | +2.2% | +2.2% | +2.2% | +2.2% | -4.8% | -5.2% | +43.6% | +5.6% | -38.4% | |
| – | +72.2% | +57.7% | -18.9% | -25.5% | -1.2% | -12.4% | +8.6% | +48.6% | -37.0% | +48.7% | -45.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -14.7% | -10.9% | -12.1% | -7.4% | -9.4% | -6.1% | -5.6% | +13.8% | +7.0% | -1.1% | -33.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +0.6% | +1.1% | +0.1% | -0.3% | +1.4% | +1.9% | +7.3% | -6.2% | +1.6% | +1.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.